Skip to main content
Signal8

CDT Equity Inc. (CDT)

CDT Equity Inc., a data-driven biopharmaceutical company, focuses on identifying, enhancing, and monetising therapeutic assets. The company’s pipeline includes AZD1656, a glucokinase activator that is in Phase II trials for the treatment of autoimmune disorders, including uveitis, Hashimoto’s thyroiditis, preterm labor, and renal transplant; AZD5658, which is in Phase I clinical trial for the treatment of Type 2 Diabetes Mellitus; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility. It also provides treatments for inflammatory disorders, oncology, dermatology, rare diseases and animal health. The company was formerly known as Conduit Pharmaceuticals Inc. and changed its name to CDT Equity Inc. in August 2025. The company was founded in 2019 and is based in Naples, Florida.

Sector: Pharmaceutical Preparations

Industry: Biotechnology

CDT Equity Inc. logo

CDT Equity Inc.

NASDAQ:CDTHealthcare
AH+5.56%$0.3800
Close$0.3600-4.51%
Mkt Cap$684K
EV-
Float1.76M
O/S1.9M
VOL317K sh
$ Vol$115K
RVOL0.13×
Inst Own0.0%
SI0.3%
Net Cash/Sh-
Dilution
CDT Equity Inc. logoNASDAQ:CDTAH$0.3800+5.56%
FormDescription
424B3
10-Q
424B3
8-K
Current Report
424B3
8-K
8.01
13D/A
424B3
8-K
3.03,5.03,9.01
424B3
13G/A
Beneficial Ownership Report (Amended)
DEF 14A
Definitive Proxy Statement
4
Statement of Changes in Beneficial Ownership
4/A
Statement of Changes in Beneficial Ownership
13D/A
3
Initial Statement of Beneficial Ownership
8-K
PRE 14A
Preliminary Proxy Statement
424B3
8-K
13G/A
Beneficial Ownership Report (Amended)
13G
Beneficial Ownership Report
13G/A
Beneficial Ownership Report (Amended)
13G/A
Beneficial Ownership Report (Amended)
424B3

1-25 of 375

…

Recent SEC filings with analysis

    CDT Equity Inc. (CDT) SEC Filings: 10-K, 10-Q, 8-K, Form 4 | Signal8